Live Breaking News & Updates on Diseases Treatment

Stay updated with breaking news from Diseases treatment. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Worldwide Neurological Diseases Treatment Industry to 2029 - Featuring Novartis, GlaxoSmithKline and Bayer Among Others


Share this article
Share this article
ResearchAndMarkets.com s offering.
This report offers strategic insights into the overall neurological diseases treatment market along with the market size and estimates for the duration 2019 to 2029. The said research study cover in-depth analysis of neurological treatment market segments based on type of drugs, diseases and different geographies further segmented by countries.
For the purpose of this study, the global neurological diseases treatment market is segmented on the basis of drug type into anticholinergic, antiepileptic, antipsychotic, hypnotic & sedative, analgesics, antihypertensive, anticoagulants, and others. Market size estimates and forecast for these segments for the period 2019 to 2029 are provided in terms of USD Mn along with the respective compounded annual growth rates (CAGRs) for the period 2021 to 2029, considering 2020 as the base year. ....

United States , South Africa , Saudi Arabia , Boehringer Ingelheim Gmb , Rivaroxaban Xarelto , Avonex Biocard , Asia Pacific , Bayer Janssen , Laura Wood , Cellular Therapies Inc , Neuroderm Ltd , Merck Co , Janssen Research Development , Zogenix Inc , Biogen Inc , Teva Pharmaceutical Industries Ltd , Alkermes Inc , Abbvie Inc , Nono Inc , Sunovion Pharmaceuticals Inc , Roche Ltd , Bayer Ag , Avanir Pharmaceuticals , Office Hours Call , P Gw Research Ltd , World Health Organization ,